Articles by James Calloway
SoFi Shares Gain Ahead of Critical Q1 Report Amid Accounting Scrutiny
SoFi Technologies shares climbed 2.1% Friday to $19.43 on heavy volume ahead of its April 29 earnings report. The fintech faces its first major update since short seller Muddy Waters questioned its accounting in March.
Netflix Shares Slide on Subdued Q2 Outlook, Hastings Board Exit
Netflix shares tumbled nearly 10% as a weak Q2 revenue and earnings projection overshadowed strong Q1 results and news of co-founder Reed Hastings' planned board departure.
FDA Peptide Review Sparks Rally for Hims & Hers Health
Shares of Hims & Hers Health climbed sharply after regulators signaled a review of peptide restrictions, a development analysts view as a positive shift for the company's growth strategy.
Hims & Hers Stock Jumps on FDA's Peptide Policy Review
Shares of Hims & Hers Health climbed sharply after the U.S. Food and Drug Administration said it will reconsider regulations on certain peptides. The company, which acquired a peptide facility last year, sees this as an opportunity to expand beyond the GLP-1 market.
Microsoft Shares Surge on Strong Azure, Copilot Demand Ahead of Q3 Earnings
Microsoft shares gained 4.5% Wednesday following a survey indicating rising enterprise adoption of Azure and Copilot. The company reports fiscal third-quarter results on April 29.
Morgan Stanley Q1 Results Surge on Trading, Wealth Management Strength
Morgan Stanley delivered record first-quarter revenue and profit, exceeding analyst forecasts. Strong performance in equities trading and wealth management fueled the results, with shares gaining in premarket trading.
LiveScore Revenue Surges Past £200M Amid UK Tax Hike Concerns
LiveScore Group reported a 15.3% revenue rise to £206.3M, with operating loss nearly halved. The results come as the UK hikes online gambling tax to 40%, potentially adding £20-25M to its tax bill.
Citigroup Q1 Earnings Surge on Strong Trading and Investment Banking
Citigroup reported a 42% surge in first-quarter profit to $5.8 billion, with revenue climbing 14% to $24.6 billion, marking its strongest quarterly performance in ten years.
J&J Q1 Earnings Surpass Expectations, Lifts 2026 Forecast
Johnson & Johnson exceeded Wall Street's first-quarter forecasts, driven by strong performance from Darzalex and Tremfya. The company raised its full-year 2026 sales guidance.


